Spyre Therapeutics, Inc. - Common Stock (SYRE)
CUSIP: 00773J202
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 78,841,667
- Total 13F shares
- 64,298,657
- Share change
- +600,718
- Total reported value
- $1,077,601,900
- Put/Call ratio
- 59%
- Price per share
- $16.76
- Number of holders
- 136
- Value change
- +$12,200,602
- Number of buys
- 64
- Number of sells
- 56
Quarterly Holders Quick Answers
What is CUSIP 00773J202?
CUSIP 00773J202 identifies SYRE - Spyre Therapeutics, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 00773J202:
Top shareholders of SYRE - Spyre Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13F
|
Company |
11%
|
9,053,034
|
$135,523,919 | — | 30 Jun 2025 | |
| Fairmount Funds Management LLC |
13F
3/4/5
|
Company · Director |
5.1%
|
4,018,101
|
$60,150,972 | — | 30 Jun 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
6.6%
from 13D/G
|
4,007,296
|
$59,989,221 | — | 30 Jun 2025 | |
| RTW INVESTMENTS, LP |
13D/G
13F
|
Company |
6.2%
|
3,621,996
|
$54,402,380 | $0 | 31 Dec 2024 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
4.1%
|
3,200,000
|
$47,904,000 | — | 30 Jun 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.9%
|
3,066,586
|
$45,906,793 | — | 30 Jun 2025 | |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
— |
4.6%
|
2,685,448
|
$40,335,429 | $0 | 31 Dec 2024 | |
| VR Adviser, LLC |
13F
|
Company |
3.4%
|
2,685,448
|
$40,201,157 | — | 30 Jun 2025 | |
| PERCEPTIVE ADVISORS LLC |
13D/G
13F
|
Company |
4.4%
|
2,574,723
|
$38,672,339 | -$185,961,697 | 31 Dec 2024 | |
| BRAIDWELL LP |
13F
|
Company |
3.3%
|
2,578,404
|
$38,598,708 | — | 30 Jun 2025 | |
| Capital International Investors |
13F
|
Company |
3%
|
2,392,541
|
$35,816,339 | — | 30 Jun 2025 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
2.6%
|
2,085,590
|
$31,221,282 | — | 30 Jun 2025 | |
| Commodore Capital LP |
13F
|
Company |
2.5%
|
1,988,084
|
$29,761,617 | — | 30 Jun 2025 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
2.4%
|
1,870,445
|
$28,000,562 | — | 30 Jun 2025 | |
| STATE STREET CORP |
13F
|
Company |
2%
|
1,595,291
|
$23,881,506 | — | 30 Jun 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
1.9%
|
1,513,478
|
$22,656,765 | — | 30 Jun 2025 | |
| Jefferies Financial Group Inc. |
13F
|
Company |
1.8%
|
1,388,854
|
$20,791,144 | — | 30 Jun 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.6%
|
1,227,232
|
$18,373,490 | — | 30 Jun 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
1.4%
|
1,079,443
|
$16,159,262 | — | 30 Jun 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
1.2%
|
930,481
|
$13,930,000 | — | 30 Jun 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
1%
|
795,275
|
$11,905,267 | — | 30 Jun 2025 | |
| Polar Capital Holdings Plc |
13F
|
Company |
0.94%
|
745,000
|
$11,152,650 | — | 30 Jun 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.85%
|
671,044
|
$10,045,534 | — | 30 Jun 2025 | |
| BAKER BROS. ADVISORS LP |
13F
3/4/5
|
Company · Director |
0.79%
|
626,703
|
$9,381,744 | — | 30 Jun 2025 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
0.78%
|
613,665
|
$9,186,565 | — | 30 Jun 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
0.77%
|
610,200
|
$9,134,694 | — | 30 Jun 2025 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.77%
|
606,678
|
$9,081,970 | — | 30 Jun 2025 | |
| EMERALD ADVISERS, LLC |
13F
|
Company |
0.72%
|
565,863
|
$8,470,969 | — | 30 Jun 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.66%
|
523,416
|
$7,835,537 | — | 30 Jun 2025 | |
| Blackstone Inc. |
13F
|
Company |
0.62%
|
489,248
|
$7,324,043 | — | 30 Jun 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.59%
|
465,152
|
$6,963,325 | — | 30 Jun 2025 | |
| UBS Group AG |
13F
|
Company |
0.59%
|
462,863
|
$6,929,059 | — | 30 Jun 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.55%
|
436,947
|
$6,541,096 | — | 30 Jun 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.53%
|
418,503
|
$6,264,990 | — | 30 Jun 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.5%
|
396,351
|
$5,933,375 | — | 30 Jun 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
0.47%
|
368,598
|
$5,517,912 | — | 30 Jun 2025 | |
| VICTORY CAPITAL MANAGEMENT INC |
13F
|
Company |
0.45%
|
354,116
|
$5,301,116 | — | 30 Jun 2025 | |
| Capital World Investors |
13F
|
Company |
0.44%
|
350,774
|
$5,251,087 | — | 30 Jun 2025 | |
| EMERALD MUTUAL FUND ADVISERS TRUST |
13F
|
Company |
0.42%
|
329,430
|
$4,931,567 | — | 30 Jun 2025 | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
0.35%
|
278,920
|
$4,175,432 | — | 30 Jun 2025 | |
| S.c.a. Candriam |
13F
|
Individual |
0.31%
|
246,030
|
$3,683,226 | — | 30 Jun 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.28%
|
223,320
|
$3,343,100 | — | 30 Jun 2025 | |
| Deep Track Capital, LP |
13F
|
Company |
0.28%
|
219,015
|
$3,278,655 | — | 30 Jun 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.27%
|
216,646
|
$3,243,190 | — | 30 Jun 2025 | |
| Capitolis Liquid Global Markets LLC |
13F
|
Company |
0.23%
|
183,000
|
$2,739,510 | — | 30 Jun 2025 | |
| ARMISTICE CAPITAL, LLC |
13F
|
Company |
0.22%
|
172,000
|
$2,574,840 | — | 30 Jun 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.17%
|
135,068
|
$2,021,968 | — | 30 Jun 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.17%
|
132,150
|
$1,978,285 | — | 30 Jun 2025 | |
| SCHRODER INVESTMENT MANAGEMENT GROUP |
13F
|
Company |
0.16%
|
129,558
|
$1,971,873 | — | 30 Jun 2025 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
0.14%
|
113,968
|
$1,706,101 | — | 30 Jun 2025 |
Institutional Holders of Spyre Therapeutics, Inc. - Common Stock (SYRE) as of Q3 2025
As of 30 Sep 2025,
Spyre Therapeutics, Inc. - Common Stock (SYRE) was held by
136 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
64,298,657 shares.
The largest 10 holders included
FMR LLC, Fairmount Funds Management LLC, BlackRock, Inc., RTW INVESTMENTS, LP, TANG CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, VR ADVISER, LLC, BRAIDWELL LP, Capital International Investors, and Driehaus Capital Management LLC.
This page lists
136
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
128
Q3 2025 holders
136
Holder diff
8
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.